No Data
No Data
Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay
Myriad Genetics Announces Incorporation of Its Proprietary HRD Platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 V2
If RFK Jr. Cuts Science Funding, These Instrument Makers May Suffer -- Barrons.com
Illumina, Inc. (ILMN) CFO Ankur Dhingra Hosts Wolfe Research 2024 Healthcare Conference (Transcript)
Because Mena announced the expansion of the TruSight Oncology product line.
The latest solutions will be showcased at the annual meeting of the Molecular Pathology Association for comprehensive variant analysis of tumors. Research and share led by customers of Illumina will provide the latest tumor analysis evidence and related content. San Diego, California, USA, November 20, 2024 /PR Newswire/ -- Illumina, a global leader in DNA sequencing and array technologies (nasdaq: ILMN), today announced the launch of the new version of its flagship cancer research testing product, TruSight Oncology 500 v2 (TSO 500 v2), for practical applications.
Express News | Illumina Inc: Trusight Oncology 500 V2 Assay Is Currently Under Development, Global Release Planned for Mid-2025
No Data
No Data
104013278 : while both counter are raise significantly
ZnWC : Ark Invest buy and sell Tesla stock to adjust the portfolio. There is a limit on how much to hold a particular stock.
Ark Invest bought 52.52K Tesla's share worth $15.15M
https://www.moomoo.com/community/feed/113444265394582?share_code=01zfkB
Sor Shi Dll OP ZnWC : I updated my post, TSLA bought about 1 B on Nov 6.